TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| IRIS International Q1 2010 Earnings Call Transcript IRIS International Inc. (IRIS)Q1 2010 Earnings CallMay 03, 2010 4:30 pm ETComplete Story » seekingalpha.com |
Glaxo's Avandia Drug Cited for Heart Risk Two new studies said the Glaxo diabetes drug Avandia is unsafe, heating up a controversy about a drug linked in a number of studies to an increased risk of heart attack and heart failure. online.wsj.com |
Sanofi-Aventis Approaches Genzyme Sanofi-Aventis has made an informal acquisition approach to biotechnology drug maker Genzyme, which has a market value of about $14 billion. online.wsj.com |
LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest [Business Wire] - BURLINGTON, N.C.----Laboratory Corporation of America® Holdings announced today that for the period of September 12, 2010 to March 11, 2011, its Zero Coupon Convertible Subordinated Notes due 2021 will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended September 8, 2010, in addition to the continued accrual of the original issue discount. us.rd.yahoo.com |
Sanofi-Aventis Makes Hostile Bid to Acquire Genzyme: Are They Overpaying? Value Expectations submits: Yesterday, France’s largest drugmaker Sanofi-Aventis (SNY) went hostile with their $18.5 billion bid for US biotech company Genzyme (GENZ) after Genzyme’s management refused the offer at the same price twice already. The news of this takeover have driven Genzyme’s share price to above $71, as the market seems to believe that Genzyme will be able to get Sanofi to raise its current $69 a share offer. Genzyme’s management rejected the $69 a share offer twice – once in July and again in August – so Sanofi has offered it to Genzyme’s investors. The offer expires on December 10.Raising its bid above $69, Sanofi would be bidding against itself, but with patent expirations and slow growth prospects – an issue that currently plagues almost every major pharmaceutical company, Sanofi might have to do just that to win over Genzyme’s investors.Complete Story » seekingalpha.com |